GSK wins speedy FDA Zejula review in ovarian cancer niche

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 24, 2019 at 7:32 PM.

  1. #1 cafead, Jun 24, 2019 at 7:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,937
    Likes Received:
    3
    via Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group. GSK picked up the med in last year's Tesaro buyout.

    article source
     
    Quote

Reply to Thread